Elevance Health raised its 2026 earnings guidance to at least $27.00 per share in adjusted diluted earnings, up from at least $26.75 set in Q1, after the insurance company reported strong second quarter results that beat analyst expectations.
The company reported Q2 2026 operating revenue of $49.8 billion, up 0.8% from $49.4 billion in the same quarter last year. Adjusted diluted earnings per share came in at $7.45, surpassing the consensus estimate of $6.18 per share.
“Our second quarter results exceeded our outlook, supported by disciplined execution and improved operating performance across our diversified portfolio,” CEO Gail K. Boudreaux said in the earnings announcement. “We are raising our 2026 adjusted EPS guidance to at least $27.00 and accelerating targeted investments in the capabilities that matter most: medical cost management, member experience, provider connectivity, operating efficiency, and Carelon’s value-based solutions.”
The company also raised its full-year 2026 operating cash flow guidance to at least $6.0 billion, reflecting confidence in underlying business strength. Management said these actions would strengthen operations and reinforce confidence in returning to at least 12% adjusted EPS growth in 2027.
Medical Cost Pressures Weigh on Margins
Despite the earnings beat, Elevance faced headwinds from rising medical costs. The benefit expense ratio—a key measure of medical claim costs relative to premiums—increased 80 basis points year-over-year to 89.7%, driven by expected elevated medical cost trends in the company’s Government businesses, particularly Medicare Advantage and Medicaid.
The medical cost challenge reflects broader industry dynamics. Industry analysts expect medical cost trends to remain elevated in 2026, affecting both group and individual health plans across the sector. The company’s Health Benefits segment operating revenue grew 3% to $42.7 billion, but operating gain declined to $0.9 billion from $1.6 billion year-over-year, partly due to higher benefit expenses and targeted workforce investments.
Elevance’s second consecutive guidance raise—following a similar raise in Q1 when the company lifted guidance to at least $26.75—signals management confidence in its ability to manage cost pressures through operational improvements and its Carelon integrated healthcare solutions business. The company paid a quarterly dividend of $1.72 per share and repurchased 0.7 million shares for $234 million during the quarter.
Sources
- Morningstar (Business Wire) — Q2 2026 earnings release with revenue, EPS, guidance raises, and segment details
- MarketBeat — Q2 2026 earnings confirmation and guidance figures
- TradingView — Q2 2026 revenue and adjusted EPS figures
- Globe and Mail — Full-year 2026 adjusted EPS guidance raise to at least $27.00
- Best Version Media — Industry context on medical cost trends in 2026
